A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

NCT05900154 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

128

Enrollment

INDUSTRY

Sponsor class

Conditions

RESPIRATORY SYNCYTIAL VIRUS (RSV)

Interventions

BIOLOGICAL: RSVpreF 120 µg
BIOLOGICAL: RSVpreF 60 µg

Sponsor

Pfizer